UBS maintains Gilead Sciences at Buy, raises price target to $195 from $175

What happened

UBS maintained its Buy rating on Gilead Sciences and raised its price target to $195 from $175. The new target is an 11.4% increase and implies 14.2% upside from Gilead’s Oct. 30 closing price of $170.68.

Confirmed

Global impact / market context

A higher target signals that UBS sees more potential value in Gilead shares, which may influence investor expectations and positioning. However, it is an analyst estimate, not a company forecast or a guarantee that the share price will rise.

Analyst inference

Five recent analyst targets cited for Gilead range from $175 to $200, placing UBS’s new $195 target near the upper end. The article gives no reason for UBS’s change, so it does not establish what business outlook or assumptions drove the revision.

Confirmed

What to watch

1. Compare Gilead’s future reported results and company outlook with the assumptions behind UBS’s higher target; the article does not identify those assumptions. Analyst inference
2. Watch for subsequent analyst updates, since the five recent targets cited range from $175 to $200 and could indicate whether views are changing. Analyst inference
3. The article reports UBS’s Buy rating and $195 target, but provides no company guidance, earnings figures, or explanation for the target increase. Confirmed

Evidence

• Original source link unavailable